Investor Alert: Update on Proposed Acquisition of Winston Hotels, Inc.
[Press Release] PrimeNewswire via Yahoo! Finance - Feb 27 1:53 PM
DALLAS, Feb. 27, 2007 — On February 21, 2007, Winston Hotels, Inc. entered into a definitive agreement and plan of merger with Wilbur Acquisition Holding Company, LLC for $14.10 per share.Save
Langhorne firm’s abdominal-surgery tool gets FDA OK / Business news in brief
The Philadelphia Inquirer - Feb 07 12:34 AM
A Langhorne device company, Power Medical Interventions Inc., said the Food and Drug Administration had approved its tool that enables surgeons to perform abdominal surgery without incisions. The firm said surgeons could use the device to perform laparoscopic surgery through the gastrointestinal tract without cutting or puncturing the abdominal wall. The technology is designed to reduce pain, …Save
Virgin Media Takes on Competitors With New TV Sports Offer
Elite TV - Feb 15 9:42 AM
For just GBP26 a month, Virgin Media (NASDAQ: VMED) is offering sports fans Sky Sports 1, 2, 3 and Xtra, together with 39 other digital TV channels including E4, CBeebies and ITV2.Save
Alfacell Adds Michael S. Kinch Ph.D. to Scientific Advisory Board
[Press Release] PR Newswire via Yahoo! Finance - Feb 28 5:30 AM
Alfacell Corporation today announced the addition of Michael S. Kinch Ph.D. to its scientific advisory board.Save
After cleanup time, town talks buyout
Casper Star-Tribune - Feb 05 1:16 AM
LIBBY, Mont. — For more than 65 years, lethal asbestos fibers from a nearby vermiculite mine contaminated this small town and its people.Save
James Hardie’s Hellicar Quits on Asbestos Suit (Update2)
Bloomberg.com - Feb 19 10:38 PM
Feb. 20 (Bloomberg) — James Hardie Industries NV Chairwoman Meredith Hellicar and two other directors quit after being sued by Australia’s securities regulator for misleading investors over the cost of compensating people sickened by asbestos.Save
Alfacell Creates New Board Committees
[Press Release] PR Newswire via Yahoo! Finance - Feb 12 10:20 AM
Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer and other life-threatening diseases, today announced the creation of two board committees that will oversee the company’s clinical and pre-clinical research efforts as well as its commercial and business development activities.Save